Literature DB >> 16055284

Treatment adherence in the Estonian postmenopausal hormone therapy (EPHT) trial [ISRCTN35338757].

Sigrid Vorobjov1, Sirpa-Liisa Hovi, Piret Veerus, Heti Pisarev, Mati Rahu, Elina Hemminki.   

Abstract

OBJECTIVE: To investigate treatment adherence and factors related to non-adherence in the Estonian postmenopausal hormone therapy (EPHT) trial.
METHODS: A total of 1823 postmenopausal women aged 50-64 years were recruited into the EPHT trial from 1999 to 2001. They were randomised into the blind group receiving continuous orally administered postmenopausal hormone therapy (PHT) or a placebo and to a non-blind group receiving open-label PHT or no drugs. A woman was classified as non-adherent, if she had stopped treatment for at least 6-month period in treatment arms or used PHT for at least 6-month period in the control group. Adherence was calculated by the Kaplan-Meier method, and factors affecting adherence were studied with Cox proportional hazard modelling.
RESULTS: The rate of adherent women declined approximately 50% during the first year in all treatment arms. Less than 10% of the control group women started taking prescribed PHT. Older women, with lower education, with only one birth, never used oral contraceptives (OC), with lower physical activity or who were dissatisfied with the information received from the trial staff, were more likely to discontinue. In treatment arms, the two most often cited reasons for non-adherence were side-effects and woman's loss of interest in participation. Control group women started PHT due to the menopausal symptoms or on doctor's recommendation.
CONCLUSIONS: The adherence was similar to that found for PHT use in everyday life. Higher adherence was related to younger age, higher education, previous OC use, physical activity and satisfaction with received information.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16055284     DOI: 10.1016/j.maturitas.2005.05.001

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  8 in total

Review 1.  Long-term hormone therapy for perimenopausal and postmenopausal women.

Authors:  Jane Marjoribanks; Cindy Farquhar; Helen Roberts; Anne Lethaby; Jasmine Lee
Journal:  Cochrane Database Syst Rev       Date:  2017-01-17

2.  The effect of hormone therapy on women's quality of life in the first year of the Estonian Postmenopausal Hormone Therapy trial.

Authors:  Piret Veerus; Sirpa-Liisa Hovi; Tiina Sevón; Myra Hunter; Elina Hemminki
Journal:  BMC Res Notes       Date:  2012-04-03

3.  Results from a blind and a non-blind randomised trial run in parallel: experience from the Estonian Postmenopausal Hormone Therapy (EPHT) Trial.

Authors:  Piret Veerus; Krista Fischer; Matti Hakama; Elina Hemminki
Journal:  BMC Med Res Methodol       Date:  2012-04-04       Impact factor: 4.615

4.  Experiences of a long-term randomized controlled prevention trial in a maiden environment: Estonian Postmenopausal Hormone Therapy trial.

Authors:  Sirpa-Liisa Hovi; Piret Veerus; Mati Rahu; Elina Hemminki
Journal:  BMC Med Res Methodol       Date:  2008-08-01       Impact factor: 4.615

5.  Prevalence and risk factors of urinary incontinence among Estonian postmenopausal women.

Authors:  Fred Kirss; Katrin Lang; Karolin Toompere; Piret Veerus
Journal:  Springerplus       Date:  2013-10-17

6.  The effects of postmenopausal hormone therapy on social activity, partner relationship, and sexual life - experience from the EPHT trial.

Authors:  Elina Hemminki; Piret Veerus; Heti Pisarev; Sirpa-Liisa Hovi; Päivi Topo; Helle Karro
Journal:  BMC Womens Health       Date:  2009-06-08       Impact factor: 2.809

7.  Variability of bothersome menopausal symptoms over time--a longitudinal analysis using the Estonian postmenopausal hormone therapy trial (EPHT).

Authors:  Elina Hemminki; Elena Regushevskaya; Riitta Luoto; Piret Veerus
Journal:  BMC Womens Health       Date:  2012-12-21       Impact factor: 2.809

8.  Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial.

Authors:  Piret Veerus; Krista Fischer; Sirpa-Liisa Hovi; Helle Karro; Mati Rahu; Elina Hemminki
Journal:  BMC Womens Health       Date:  2008-03-26       Impact factor: 2.809

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.